Byetta Is “Approvable” As Stand-Alone Therapy
Lilly/Amylin'sByetta type 2 diabetes agent is "approvable" at FDA as a stand-alone therapy in conjunction with the April 29 approval of exenatide as an adjunct to other oral treatments, the firms said
Lilly/Amylin'sByetta type 2 diabetes agent is "approvable" at FDA as a stand-alone therapy in conjunction with the April 29 approval of exenatide as an adjunct to other oral treatments, the firms said